Loading
KB
Kinnate Biopharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 May 2023.
Kinnate Biopharma Inc.: what insiders have been doing
Kinnate Biopharma Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Kinnate Biopharma Inc. in twelve months, the latest record being from 5 April 2024.
Our records for Kinnate Biopharma Inc. go back to 2022, with 5 purchases and no sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€6M
5 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Net income-US$97.5M
Last declaration on 5 April 2024
Declarations42 total
9,671,643 sharesCommon StockSEC:0001415889-24-010434:0
9,671,643 sharesCommon StockSEC:0001104659-24-044187:0
2,186 sharesCommon StockSEC:0001415889-24-010433:0
1,368,339 sharesCommon StockSEC:0000947871-24-000353:0
64,087 sharesCommon StockSEC:0001415889-24-010431:0
1,368,339 sharesCommon StockSEC:0000947871-24-000354:0
27,578 sharesCommon StockSEC:0001415889-24-010424:0
66,377 sharesCommon StockSEC:0001415889-24-010428:0
1,506 shares@ US$2.5910.3% of flowCommon StockSEC:0001415889-24-006755:0
558 shares@ US$2.591.0% of flowCommon StockSEC:0001415889-24-006754:0
558 shares@ US$2.5910.3% of flowCommon StockSEC:0001415889-24-006753:0
1,459 shares@ US$2.258.6% of flowCommon StockSEC:0001209191-23-057455:0
541 shares@ US$2.250.9% of flowCommon StockSEC:0001209191-23-057457:0
541 shares@ US$2.258.6% of flowCommon StockSEC:0001209191-23-057454:0
1,459 shares@ US$2.359.0% of flowCommon StockSEC:0001209191-23-048429:0
541 shares@ US$2.350.9% of flowCommon StockSEC:0001209191-23-048424:0
541 shares@ US$2.359.1% of flowCommon StockSEC:0001209191-23-048426:0
541 shares@ US$4.301.7% of flowCommon StockSEC:0001209191-23-034445:0
1,459 shares@ US$4.3016.7% of flowCommon StockSEC:0001209191-23-034447:0
541 shares@ US$4.3016.7% of flowCommon StockSEC:0001209191-23-034444:0
1,550,956 shares@ US$2.80100.0% of flowCommon StockSEC:0001209191-23-028537:0
Canonical exit: 6 Aug 2023 (T+90)
▲
Same trade as the filing by James B. Tananbaum, counted once · View ↗
1,550,956 shares@ US$2.80100.0% of flowCommon StockSEC:0001209191-23-028527:0
Canonical exit: 6 Aug 2023 (T+90)
83,459 shares@ US$2.7511.9% of flowCommon StockSEC:0000947871-23-000540:0
Canonical exit: 2 Aug 2023 (T+90)
▲
Same trade as the filing by Carl l. Gordon, counted once · View ↗
83,459 shares@ US$2.7511.9% of flowCommon StockSEC:0000947871-23-000541:0
Canonical exit: 2 Aug 2023 (T+90)
60,998 shares@ US$2.558.1% of flowCommon StockSEC:0000947871-23-000516:0
Canonical exit: 27 Jul 2023 (T+90)
25 of 42 declarations
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer. It employs innovative approaches to identify and develop drugs that address unmet medical needs.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
